Previous 10 | Next 10 |
Market Pulse The month of May thus far has been mostly a downward ride with an occasional rise, proving to be a mere bunny bump, as indexes have eroded persistently on the lack of a trade resolution with China, an outcome that at one point was considered to be almost in the bag. This is rais...
Stellar Biotechnologies (NASDAQ: SBOT ) +73% . More news on: Stellar Biotechnologies, Inc., Eltek Ltd., Williams-Sonoma, Inc., Stocks on the move, Read more ...
Iovance Biotherapeutics (NASDAQ: IOVA ) is up 2% premarket on light volume on the heels of updated data on tumor-infiltrating lymphocyte (TIL) candidates LN-145 in cervical cancer ( innovaTIL-04 study ) and lifileucel in melanoma ( innovaTIL-01 study ). The results will be pres...
Complete Response rate of 11 percent observed in the LN-145 study in cervical cancer Median duration of response has not been reached at 7.4 month median follow-up in the ongoing study of LN-145 in advanced cervical cancer Median duration of response has not been reached at 8.8 mo...
SAN CARLOS, Calif., May 31, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the company plans to participate in the...
Iovance Biotherapeutics ( IOVA -3.2% ) has entered into a lease agreement to build an ~136,000 square foot commercial-scale production facility in Philadelphia for commercial and clinical production of autologous TIL products, including its candidate lifileucel. More news on: Iovance B...
SAN CARLOS, Calif., May 29, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it has entered into a lease agreement t...
Netshoes (NYSE: NETS ) +36% on takeover offer report. More news on: Netshoes (Cayman) Limited, Avon Products, Inc., Tonix Pharmaceuticals Holding Corp., Stocks on the move, Read more ...
The FDA designates Iovance Biotherapeutics' (NASDAQ: IOVA ) LN-145 a Breakthrough Therapy for the treatment of recurrent, metastatic, or persistent cervical cancer that has progressed on or after chemotherapy. More news on: Iovance Biotherapeutics, Inc., Healthcare stocks news, Stoc...
SAN CARLOS, Calif., May 22, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the U.S. Food and Drug Administration (...
News, Short Squeeze, Breakout and More Instantly...
Iovance Biotherapeutics Inc. Company Name:
IOVA Stock Symbol:
NASDAQ Market:
Iovance Biotherapeutics Inc. Website:
SAN CARLOS, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its first quarter 2024 ...
2024-04-28 14:44:00 ET There's a lot of excitement around Iovance Biotherapeutics (NASDAQ: IOVA) as its shares are up over 40% year-to-date. Investors and analysts both see even more upside for this mid-cap biotech stock in the long run. Today, however, the company remains deepl...
SAN CARLOS, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biote...